{"id":522774,"date":"2021-08-04T06:53:06","date_gmt":"2021-08-04T10:53:06","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/therapeuticsmd-announces-second-quarter-2021-financial-results\/"},"modified":"2021-08-04T06:53:06","modified_gmt":"2021-08-04T10:53:06","slug":"therapeuticsmd-announces-second-quarter-2021-financial-results","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/therapeuticsmd-announces-second-quarter-2021-financial-results\/","title":{"rendered":"TherapeuticsMD Announces Second Quarter 2021 Financial Results"},"content":{"rendered":"

<\/p>\n

TherapeuticsMD Announces Second Quarter 2021 Financial Results<\/b><\/p>\n

\n– 2Q21 total net product revenue increased by 17% over 1Q21 to $23 million –\n<\/p>\n

\n– ANNOVERA\u00ae<\/sup> prescription growth supported by improved access to providers and increased telemedicine options for patients –\n<\/p>\n

\n– Prescriptions for IMVEXXY\u00ae grew by 8% over 1Q21, outpacing the VVA market –\n<\/p>\n

\n– Centers for Medicare and Medicaid Services recommended that ANNOVERA receive its own unique national J-Code that could be live as early as Q421 –\n<\/p>\n

\n– vitaCare signed new customer and pipeline continues to grow –\n<\/p>\n

\n– Conference call scheduled for 8:30 a.m. ET today –\n<\/p>\n

BOCA RATON, Fla.–(BUSINESS WIRE<\/a>)–
\nTherapeuticsMD, Inc. (\u201cTXMD\u201d or the \u201cCompany\u201d) (NASDAQ: TXMD), an innovative, leading women\u2019s healthcare company, today reported financial results for the second quarter ended June 30, 2021.\n<\/p>\n

\n\u201cWe continue to make steady progress in line with our expectations related to ANNOVERA and IMVEXXY driving prescription growth, net margins and broader patient access. Importantly, we are seeing improved access to health care providers for our sales force and expansion of our relationships in the telemedicine channel and believe we are well positioned to grow our products across all channels. Our overall volumes and net revenues were very healthy, and vitaCare prescription services is building the foundation for growth in the future. vitaCare recently signed its third customer contract and has a strong pipeline of more than 30 potential customers. In addition, we continue to evaluate investment into vitaCare, including potentially selling a minority stake, which could provide a non-dilutive source of capital for TXMD shareholders,\u201d said Robert G. Finizio, Chief Executive Officer of TherapeuticsMD.\n<\/p>\n

Second Quarter 2021 Financial Results and Business Highlights<\/b><\/p>\n

Net Product Revenue<\/b><\/p>\n\n\n\n\n\n\n\n\n\n\n\n
\n\n\n

\nThree Months Ended\n<\/p>\n<\/td>\n<\/tr>\n

\n\n\n

\nJune 30,\n<\/p>\n<\/td>\n

\n\n

\nMarch 31,\n<\/p>\n<\/td>\n<\/tr>\n

\n\n\n

\n2021\n<\/p>\n<\/td>\n

\n\n

\n2020\n<\/p>\n<\/td>\n

\n\n

\n2021\n<\/p>\n<\/td>\n<\/tr>\n

ANNOVERA<\/td>\n\n\n

\n$\n<\/p>\n<\/td>\n

\n

\n9,555\n<\/p>\n<\/td>\n

\n\n

\n$\n<\/p>\n<\/td>\n

\n

\n1,835\n<\/p>\n<\/td>\n

\n\n

\n$\n<\/p>\n<\/td>\n

\n

\n8,750\n<\/p>\n<\/td>\n<\/tr>\n

IMVEXXY<\/td>\n\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n9,838\n<\/p>\n<\/td>\n

\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n5,086\n<\/p>\n<\/td>\n

\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n7,012\n<\/p>\n<\/td>\n<\/tr>\n

BIJUVA<\/td>\n\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n2,156\n<\/p>\n<\/td>\n

\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n1,352\n<\/p>\n<\/td>\n

\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n2,445\n<\/p>\n<\/td>\n<\/tr>\n

Prescription vitamin<\/td>\n\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n1,452\n<\/p>\n<\/td>\n

\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n2,428\n<\/p>\n<\/td>\n

\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n1,425\n<\/p>\n<\/td>\n<\/tr>\n

Product revenue, net<\/td>\n\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n23,001\n<\/p>\n<\/td>\n

\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n10,701\n<\/p>\n<\/td>\n

\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n19,632\n<\/p>\n<\/td>\n<\/tr>\n

License revenue<\/td>\n\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n\u2014\n<\/p>\n<\/td>\n

\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n\u2014\n<\/p>\n<\/td>\n

\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n234\n<\/p>\n<\/td>\n<\/tr>\n

Total revenue, net<\/td>\n\n\n

\n$\n<\/p>\n<\/td>\n

\n

\n23,001\n<\/p>\n<\/td>\n

\n\n

\n$\n<\/p>\n<\/td>\n

\n

\n10,701\n<\/p>\n<\/td>\n

\n\n

\n$\n<\/p>\n<\/td>\n

\n

\n19,866\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

ANNOVERA (segesterone acetate and ethinyl estradiol vaginal system)<\/b><\/p>\n